Our Company2020-11-11T10:52:01-07:00

OUR COMPANY

RARE PHARMA-GRADE BARIUM SULFATE AND IODINE IN NORTH AMERICA

  • Voyageur Pharmaceuticals Ltd. (VM: TSX-V, OTC: VVYRF, Forum) is developing its 100% owned high grade barium sulfate project in BC, Canada.
  • VM business plan is to develop its advanced stage pharmaceutical grade barium sulfate project, Frances Creek. Voyageur is developing barium contrast radiographic suspension products for the pharmaceutical industry.
  • Frances Creek bulk sample tentatively scheduled for  Q3, 2021
  • VM’s pharmaceutical grade barite is naturally occurring with grades as high as 99.26% BaSO4 in-situ, which is very rare.
  • Voyageur has achieved a 98.6% BaSO4 product with SGS Minerals. The only barite sold in  the market  place, grading +98%, is man made in a lab using  an expensive manufacturing processing.
  • The only other source of natural pharmaceutical grade barite is from China.
  • China only exports 5% of their production of pharmaceutical barite, allocating 95% for their  domestic market.
  • The pharmaceutical industry primarily uses expensive man made barium sulfate for the  radiographic market.

Vertical Integration = High Growth

June 29th, 2021|

https://investorintel.com/markets/biotech-healthcare/biotech-intel/voyageur-pharmaceuticals-strategy-is-to-remove-the-middleman-and-supply-radiographic-contrast-media-direct-from-mine-to-the-x-ray-center/

Financed & Moving Forward

June 22nd, 2021|

https://investorintel.com/investorintel-video/brent-willis-on-voyageur-pharmaceuticals-competitive-suite-of-barium-radiographic-contrast-media-products/

COMPANY NEWS ARCHIVES
Go to Top